纳米药物递送系统在前列腺癌治疗中的应用

前列腺癌（PCa）是全球最常见的男性泌尿生殖系统恶性肿瘤。手术、内分泌治疗、放疗和化疗是PCa的主要临床治疗选择。纳米药物递送系统具有良好的可控释放特性和较好的肿瘤靶向能力,并可通过增强的渗透性和保留（EPR）效应被动靶向肿瘤。通过精巧的设计组装和外表修饰赋予纳米递药系统与众不同的肿瘤治疗效果。本文介绍用于PCa治疗的先进纳米药物递送系统以及未来发展。

Research Progress of Nano-drug Delivery System in Prostate Cancer

Prostate cancer (PCa) is the most frequent genitourinary cancer in men globally. The primary clinical treatment options for PCa are surgery, endocrine therapy, radiation, and chemotherapy. The nano-drug delivery device provides improved tumor targeting and controlled release features. The capacity to passively target tumors via greater permeability and retention (EPR) and increased active targeting by modification of antibodies, peptides, aptamers, or small molecules to identify particular organ or cell receptors can give further advanced benefits. The design, assembly, and surface modification of nano-drug delivery devices confer different therapeutic effects in malignancies. Organic such as micelles, nanogels and dendrimers and inorganic such as carbon nanotubes, gold nanoparticles, magnetic nanoparticles, mesoporous dioxide silicon nanoparticles, and quantum dots nanocarriers are the most common forms of nanocarriers. Traditional prostate cancer therapies include drawbacks such as adverse effects, minimal effectiveness, and inadequate absorption. Chemotherapy can result in the development of drug resistance in prostate cancer, hence the development of new, effective, customized therapies is essential. Because of their intrinsic nanoscale features, nano-drug delivery systems, such as nano-delivery systems paired with chemotherapy, radiation, photodynamic treatment, and hyperthermia, can increase the therapeutic benefits of conventional therapeutic agents. Such therapies have the potential to significantly increase the survival rate of prostate cancer patients. This article discusses sophisticated nano-drug delivery technologies for PCa treatment, as well as its future potential.